WEST LAFAYETTE – Bioscience Vaccines Inc. and the U.S. Army Medical Research Institute of Infectious Diseases have signed a contract to test the company’s Matrix Immune Modulator with a biodefense vaccine.
Bioscience Vaccines is based in the Purdue Research Park.
As part of their physical training and preparation, soldiers go through a series of eight injections with biodefense vaccines. The addition of Bioscience Vaccines MIM technology may make it possible to decrease the number of injections given to a soldier.
“We are pleased with the opportunity to collaborate with the U.S. Department of Defense in the development of their biodefense strategies,” said Anthony Hubbard, executive vice president of Bioscience Vaccines. “Pending the results of the agreement, BVI’s next step will be to leverage the results to obtain additional funding for follow-on testing and to move onto a second phase of testing with the U.S. Army Medical Research Institute of Infectious Diseases.”
